Sumitomo Mitsui Trust Group Inc. Has $33.05 Million Stake in United Therapeutics Co. (NASDAQ:UTHR)

Sumitomo Mitsui Trust Group Inc. reduced its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 93,673 shares of the biotechnology company’s stock after selling 5,736 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 0.21% of United Therapeutics worth $33,052,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of UTHR. Bleakley Financial Group LLC lifted its stake in shares of United Therapeutics by 58.1% in the fourth quarter. Bleakley Financial Group LLC now owns 1,059 shares of the biotechnology company’s stock worth $374,000 after acquiring an additional 389 shares during the period. Meritage Portfolio Management lifted its position in shares of United Therapeutics by 12.2% in the 4th quarter. Meritage Portfolio Management now owns 1,446 shares of the biotechnology company’s stock worth $510,000 after purchasing an additional 157 shares during the period. Trust Point Inc. boosted its stake in shares of United Therapeutics by 45.5% in the 4th quarter. Trust Point Inc. now owns 1,697 shares of the biotechnology company’s stock valued at $599,000 after purchasing an additional 531 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of United Therapeutics by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,466 shares of the biotechnology company’s stock worth $3,340,000 after buying an additional 909 shares during the period. Finally, Caprock Group LLC increased its position in shares of United Therapeutics by 16.3% during the fourth quarter. Caprock Group LLC now owns 792 shares of the biotechnology company’s stock worth $279,000 after buying an additional 111 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $353.31 on Wednesday. The company has a 50-day moving average price of $362.06 and a 200-day moving average price of $358.24. The stock has a market capitalization of $15.78 billion, a P/E ratio of 15.52, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $210.64 and a 1 year high of $417.82.

Insider Activity at United Therapeutics

In other news, EVP Paul A. Mahon sold 7,700 shares of the firm’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $367.36, for a total value of $2,828,672.00. Following the transaction, the executive vice president now owns 36,710 shares in the company, valued at $13,485,785.60. This trade represents a 17.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $372.75, for a total value of $3,727,500.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $960,576.75. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 121,864 shares of company stock valued at $44,516,965. 11.90% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of analysts have commented on UTHR shares. The Goldman Sachs Group upped their price target on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research report on Friday, November 1st. Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 16th. LADENBURG THALM/SH SH increased their price target on United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, Argus lifted their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $382.08.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.